Previous 10 | Next 10 |
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett Writing about antibiotic innovators is a quandary for me because I have to balance between the need for investment profits for investors vs. my social responsibility. It's an inte...
Outlook Therapeutics (NASDAQ: OTLK ) +26% as the company is poised to add to ONS-5010. More news on: Outlook Therapeutics, Inc., Orion Energy Systems, Inc, Sprint Corporation, Stocks on the move, Read more ...
The Medicines Company (NASDAQ: MDCO ) is up 9 % premarket, albeit on only 461 shares, in reaction to preliminary data from the ongoing Phase 2 open-label extension study, ORION-3 , evaluating twice-a-year dosing with inclisiran sodium 300 mg in patients with high cardiovascul...
This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking David Einhorn's Greenlig...
Interim results from ongoing ORION-3 study demonstrated sustained lowering of LDL-C by more than 50 percent, with time-averaged absolute reductions of 59.4 mg/dL No material safety issues observed in the study Pivotal Phase 3 readouts for inclisiran expected in 3Q-2019 followed by ...
Noteworthy events during the week of May 12 - 18 for healthcare investors. More news on: Johnson & Johnson, Insmed Incorporated, Innovate Biopharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Company management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from ongoing ORION-3 study The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, a...
The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). A live audio webcast wil...
As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch ...
News, Short Squeeze, Breakout and More Instantly...
The Medicines Company Company Name:
MDCO Stock Symbol:
NASDAQ Market:
The Medicines Company Website:
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3...
Shares of Meritor (NYSE: MTOR) , a global supplier of drivetrain, braking, and other aftermarket automotive solutions for vehicles, jumped as high as 16% Tuesday morning after markets digested the announcement that Meritor will join the S&P SmallCap 600 index. The announcement actually c...
NEW YORK , Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Monday, January 6 : NexPoint Residential Trust Inc. (NYSE: NXRT) will replace Avon Products Inc. (NYSE: AVP). Natura...